Stiff Person Syndrome (SPS) Clinical Trials and Treatments

Stiff Person Syndrome is an autoimmune disorder of the central nervous system involving antibodies against glutamate decarboxylase (GAD), the enzyme producing GABA from glutamate. Reduced GABA results in loss of inhibitory control over motor neuron firing, leading to unopposed motor neuron activation and muscle rigidity. Two main antibody types are identified: anti-GAD65 antibodies (most common, 50-80% of patients) and anti-amphiphysin antibodies (present in ~30% of cases, particularly paraneoplastic SCLC-associated SPS).

The most common symptoms of Stiff Person Syndrome include Progressive muscle stiffness, typically starting in legs and trunk, Severe, painful muscle spasms triggered by sudden movements or loud noises, Muscle rigidity that progresses slowly over weeks to months, Abnormal postures and gait disturbance, Anxiety and hyperstartle response, among others. Extremely rare with approximately 1-2 cases per million people; estimated 300-500 affected individuals in North America. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Stiff Person Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Stiff-Person Syndrome combines therapies that enhance the neurotransmitter GABA with immunomodulatory approaches targeting the autoimmune process. GABA-enhancing drugs like baclofen and benzodiazepines improve spasticity, while immunosuppressive agents and newer antibody-targeting approaches address the underlying autoimmune attack on GABAergic neurons.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Stiff Person Syndrome: Diazepam (diazepam oral). Corticosteroids and immune globulins count once each.

The exact cause of Stiff Person Syndrome is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Considered autoimmune; most patients have anti-GAD65 antibodies (less often amphiphysin or glycine receptor). No genetic test has a diagnostic role. Extremely rare with approximately 1-2 cases per million people; estimated 300-500 affected individuals in North America. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Stiff Person Syndrome. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Considered autoimmune; most patients have anti-GAD65 antibodies (less often amphiphysin or glycine receptor). No genetic test has a diagnostic role.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Stiff Person Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Stiff Person Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.